BARCELONA, Spain--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) announced new data presented today on the safety and effectiveness of Medtronic’s CoreValve system via a novel, subclavian approach. The data reported procedural success of 100 percent; 24-hour survival of 100 percent; and 30-day survival of 89 percent. The available 30-day analysis also demonstrated clinical improvement in heart failure symptoms with 76 percent of the patients gaining at least a one-stage NYHA class and one-third improving by at least two stages.
